Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH

NEW YORK and LONDON, January 3rd, 2017

Phase II trial in eculizumab resistant PNH expected to expand into US

Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed on December 29th, 2016, its Investigational New Drug Application (IND) for the clinical development of Coversin™ in patients with PNH. The FDA’s allowance of the IND permits the Company to expand its clinical program for the development of Coversin in PNH to the United States. The Company has one currently treated eculizumab resistant PNH patient who has been on Coversin for approximately 11 months pursuant to an approved clinical protocol in the Netherlands and plans to open this ongoing Phase II trial of Coversin in eculizumab resistant PNH in the United States.

Click here to see full release